Clinical Trial

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Trial Details
NCT Number NCT07420010
Lead Sponsor Weijia Fang, MD
Conditions Ovarian Cancer, Mesothelioma, Colon Cancer
Enrollment 24 participants
Start Date 2026-03-15
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-19